BioNxt Solutions Inc. (BNXT) | WebDisclosure

Basculer en Français

8295	Companies
114846	Keywords
55288	Articles
62438	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 09/09/2024 at 22:35, 2 months 11 days ago

BioNxt reçoit un rapport d'examen international positif de l'Office européen des brevets

Sclérose En Plaques Solutions BioNxt Office Européen Des Brevets Administration Sublinguale De Médicaments Myasthénie Grave
PRESS RELEASE

published on 09/09/2024 at 22:30, 2 months 11 days ago

BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
BioNxt Solutions Inc. receives positive international examination report from the European Patent Office for sublingual delivery patent application. Company to expand patent portfolio for neurodegenerative diseases and MS market

BioNxt Solutions Inc. Multiple Sclerosis Patent Application Neurodegenerative Diseases European Patent Office
BRIEF

published on 08/15/2024 at 09:10, 3 months 6 days ago

BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations

Partnership Cladribine Pharmaceutical Development BioNxt Solutions Gen-Plus GmbH
BRIEF

published on 08/15/2024 at 09:10, 3 months 6 days ago

BioNxt signe une lettre d'intention avec Gen-Plus GmbH & Co KG pour d'éventuelles collaborations commerciales

Partenariat Cladribine Développement Pharmaceutique Solutions BioNxt Gen-Plus GmbH
PRESS RELEASE

published on 08/15/2024 at 09:05, 3 months 6 days ago

BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
BioNxt Solutions Inc. signs non-binding LOI with Gen-Plus GmbH & Co KG, part of Conscio Group, for potential cooperation in pharmaceutical products and clinical trials. Details to follow

Clinical Trials Pharmaceutical BioNxt Solutions Inc. LOI Gen-Plus GmbH
BRIEF

published on 07/17/2024 at 09:10, 4 months 4 days ago

BioNxt signe une déclaration de travail avec le CRDMO international pour le développement de la cladribine ODF

Sclérose En Plaques Développement Pharmaceutique Solutions BioNxt Cladribine ODF CRDMO
BRIEF

published on 07/17/2024 at 09:10, 4 months 4 days ago

BioNxt Signs Statement of Work with International CRDMO for Cladribine ODF Development

Multiple Sclerosis Pharmaceutical Development BioNxt Solutions Cladribine ODF CRDMO
PRESS RELEASE

published on 07/17/2024 at 09:05, 4 months 4 days ago

BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
BioNxt Solutions Inc. signs agreement with German CRDMO for Cladribine oral dissolvable film development program targeting the lucrative multiple sclerosis market

BioNxt Solutions Inc. Cladribine CRDMO Oral Dissolvable Film MS Market
BRIEF

published on 07/09/2024 at 09:10, 4 months 12 days ago

BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization

Drug Development Pharmaceutical Market Master Services Agreement BioNxt Solutions Cladribine ODF
BRIEF

published on 07/09/2024 at 09:10, 4 months 12 days ago

BioNxt signe un accord-cadre de services avec une organisation internationale de recherche, de développement et de fabrication sous contrat

Marché Pharmaceutique Développement De Médicaments Solutions BioNxt Cladribine ODF Contrat-cadre De Services

Accesswire

Published on 11/21/2024 at 10:03, 1 hour 26 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 1 hour 29 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 2 hours 29 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 54 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 11 hours 4 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 11:01, 28 minutes ago

Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 11:00, 29 minutes ago

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Published on 11/21/2024 at 10:56, 32 minutes ago

ABO Energy closes sale for two Battery Projects in South Africa
Published on 11/21/2024 at 10:30, 59 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 1 hour 24 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO

Les Echos

Published on 11/21/2024 at 06:58, 4 hours 31 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 31 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 31 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 15 hours 21 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 16 hours 9 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE